You have not accepted cookies yet
This content is blocked. Please accept marketing cookies. You can do this here.
A leading American pharmaceutical company needed to expand the production of life saving cell therapies to treat patients in Europe. This will support the development personalized therapy for European patients with certain blood cancers where their own cells will be processed to recognize and destroy the cancer cells.
The goal is that by the end of 2025, the project should be fully operational, be able to employ circa 700 people, and bring the production of its cell-based therapies closer to European patients.
The client decided a new facility to increase production levels and support research projects in Europe was needed to bring these treatments closer to the patients. This could save precious time for patients in Europe with aggressive blood cancers.
Arcadis carried out market intelligence studies to select the best European manufacturing facility. After the Netherlands was selected as the best suited location, Arcadis developed feasibility studies for three potential locations in the Netherlands to identify the optimal site, including retrofit and greenfield options.
Based on the outcome of the studies, a greenfield site was selected as the final location. Accordingly, Arcadis executed the full design of the new facility by supporting the build of a new 20,000 sq. meter multi-product cell therapy facility which included four drug substance and two drug product filling suites with supporting utilities labs, offices, and logistical facilities.
“This will be our first European cell therapy facility, making it the company's fifth worldwide. The European facility will have the latest technologies and production equipment. This will help develop personalized therapy for European patients with certain blood cancers where their own cells will be processed to recognize and destroy the cancer cells.”